IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.852
EU - Europa 2.035
AS - Asia 1.120
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 4
SA - Sud America 4
OC - Oceania 1
Totale 6.028
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.839
IT - Italia 776
IE - Irlanda 574
SG - Singapore 409
HK - Hong Kong 277
CN - Cina 188
VN - Vietnam 140
SE - Svezia 124
UA - Ucraina 117
FI - Finlandia 100
DE - Germania 78
RU - Federazione Russa 60
RO - Romania 50
KR - Corea 40
GB - Regno Unito 29
FR - Francia 28
BE - Belgio 23
AT - Austria 18
CZ - Repubblica Ceca 18
IN - India 16
CH - Svizzera 15
TR - Turchia 14
UZ - Uzbekistan 12
NL - Olanda 9
CA - Canada 6
CI - Costa d'Avorio 6
PL - Polonia 6
IR - Iran 4
MX - Messico 4
PH - Filippine 4
SC - Seychelles 4
GR - Grecia 3
JP - Giappone 3
LB - Libano 3
A2 - ???statistics.table.value.countryCode.A2??? 2
DK - Danimarca 2
EC - Ecuador 2
EU - Europa 2
IL - Israele 2
LT - Lituania 2
PA - Panama 2
TW - Taiwan 2
BO - Bolivia 1
CL - Cile 1
CR - Costa Rica 1
ES - Italia 1
GH - Ghana 1
ID - Indonesia 1
IM - Isola di Man 1
IQ - Iraq 1
KG - Kirghizistan 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MA - Marocco 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SA - Arabia Saudita 1
Totale 6.028
Salva come PNG Salva come JPEG
Città #
Chandler 594
Dublin 568
Perugia 389
San Mateo 384
Singapore 323
Hong Kong 277
Boardman 206
Santa Clara 151
Dong Ket 140
Altamura 131
Medford 107
Princeton 105
Lawrence 101
Ann Arbor 81
Wilmington 66
Andover 63
Jacksonville 57
Beijing 51
Helsinki 50
Bucharest 43
Seoul 37
Des Moines 27
Dearborn 26
Rome 26
Redmond 25
Los Angeles 24
Brussels 23
New York 23
Foligno 22
San Paolo di Civitate 20
Houston 19
Munich 18
Norwalk 18
Redwood City 17
Dallas 16
Assisi 15
Ashburn 14
Izmir 14
Saint Petersburg 14
Shanghai 13
Menlo Park 12
Brno 11
Vienna 11
Woodbridge 9
Chicago 8
Collazzone 8
Falls Church 8
Abidjan 6
Cambridge 6
Guangzhou 6
Milan 6
Nanning 6
Shenzhen 6
Terni 6
Fairfield 5
Fremont 5
Amsterdam 4
Bastia 4
Bengaluru 4
Bologna 4
Frankfurt Am Main 4
Nuremberg 4
Olomouc 4
Paris 4
San Diego 4
Tappahannock 4
Alappuzha 3
Ancona 3
Campobasso 3
Changsha 3
Macerata 3
Moscow 3
Osimo 3
Padova 3
Rohtak 3
Tokyo 3
Toronto 3
Anaheim 2
Auburn Hills 2
Baotou 2
Bhubaneswar 2
Chiajna 2
Copenhagen 2
Davao City 2
Den Haag 2
Dong-gu 2
Florence 2
Hefei 2
Jinan 2
Lappeenranta 2
Lausanne 2
Melissa 2
Mirano 2
Montréal 2
Nanjing 2
Newark 2
Piscataway 2
Rocca Di Papa 2
Sassari 2
Selargius 2
Totale 4.536
Salva come PNG Salva come JPEG
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 131
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 119
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 109
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 109
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 97
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 97
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 93
Mesenchymal cells: a vehicle for gene therapy 92
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 92
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 90
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 90
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 89
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 88
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 84
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 84
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 82
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 80
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 77
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 76
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 74
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 73
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 72
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 71
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 71
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 70
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 69
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 69
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 69
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 69
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 67
T regulatory cell separation for clinical application. 67
BRAF mutations in hairy-cell leukemia. 66
Mutant NPM1 Maintains the Leukemic State through HOX Expression 66
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 64
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 64
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 63
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 62
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 62
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 62
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 61
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 60
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 59
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 59
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 59
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 58
Richter's transformation in the heart 58
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 57
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 57
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 57
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 56
BCOR gene alterations in hematological diseases 56
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 53
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 52
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 52
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 51
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 51
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 51
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 50
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 49
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 48
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 48
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 47
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 46
Mesenchymal cells recruit and regulate T regulatory cells. 45
A scale of "bad" co-mutations in NPM1-driven AML 45
NPM1-mutated acute myeloid leukemia: from bench to bedside 45
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 45
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 44
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 44
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 43
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 42
Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. 42
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. 41
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 41
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 40
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. 40
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 39
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 38
Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions 38
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 38
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model 37
null 37
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 37
null 37
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 35
null 35
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 34
The landscape of BRAF transcript and protein variants in human cancer. 34
NOTCH and Graft-Versus-Host Disease 34
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse 33
A DYSREGULATED, DRUGGABLE PP2A/AKT/GSK3 beta AXIS SUSTAINS NOTCH1 SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS 32
Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics 32
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 32
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 31
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 31
The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein 28
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 28
How does the NPM1 mutant induce leukemia? 28
NOTCH1 Aberrant Activation Is a Common Nonmutational Early Event in Chronic Lymphocytic Leukemia Hematopoietic Stem-Cells 28
The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence. 28
Totale 5.785
Salva come PNG Salva come JPEG
Categoria #
all - tutte 31.905
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 31.905
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020232 0 0 0 0 0 27 24 15 34 107 8 17
2020/2021586 9 23 14 25 165 31 37 29 47 21 35 150
2021/20221.312 48 376 9 44 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024918 40 81 52 35 6 24 282 10 52 31 137 168
2024/2025840 77 195 63 81 293 131 0 0 0 0 0 0
Totale 6.420